PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcellbiolHomeThe Rockefeller University PressThis articleEditorsContactInstructions for AuthorsThis issue
 
J Cell Biol. 2011 May 2; 193(3): 565–582.
PMCID: PMC3087007
Article

Occludin S408 phosphorylation regulates tight junction protein interactions and barrier function

Abstract

Although the C-terminal cytoplasmic tail of the tight junction protein occludin is heavily phosphorylated, the functional impact of most individual sites is undefined. Here, we show that inhibition of CK2-mediated occludin S408 phosphorylation elevates transepithelial resistance by reducing paracellular cation flux. This regulation requires occludin, claudin-1, claudin-2, and ZO-1. S408 dephosphorylation reduces occludin exchange, but increases exchange of ZO-1, claudin-1, and claudin-2, thereby causing the mobile fractions of these proteins to converge. Claudin-4 exchange is not affected. ZO-1 domains that mediate interactions with occludin and claudins are required for increases in claudin-2 exchange, suggesting assembly of a phosphorylation-sensitive protein complex. Consistent with this, binding of claudin-1 and claudin-2, but not claudin-4, to S408A occludin tail is increased relative to S408D. Finally, CK2 inhibition reversed IL-13–induced, claudin-2–dependent barrier loss. Thus, occludin S408 dephosphorylation regulates paracellular permeability by remodeling tight junction protein dynamic behavior and intermolecular interactions between occludin, ZO-1, and select claudins, and may have therapeutic potential in inflammation-associated barrier dysfunction.

Introduction

The tight junction (TJ) is a complex of transmembrane and peripheral membrane proteins that define the paracellular barrier (Mitic and Anderson, 1998; Tsukita and Furuse, 2002; Anderson and Van Itallie, 2009). Although binding of claudins to ZO-1 or ZO-2 is critical for TJ assembly (McNeil et al., 2006; Shin and Margolis, 2006; Umeda et al., 2006), the contributions of these and other interprotein interactions to barrier regulation in living cells are poorly understood. Recent analyses using FRAP and related techniques have demonstrated that, despite numerous physical links between TJ proteins, the molecular structure of the steady-state TJ is highly dynamic and TJ protein complexes undergo continuous remodeling with unique kinetics and varied mechanisms for each of the TJ complex components (Shen et al., 2008). We therefore hypothesized that modification of interactions between TJ proteins and resulting alterations in protein complex composition and stability might be a mechanism of barrier regulation.

ZO-1 is thought to primarily regulate paracellular permeability to uncharged macromolecules (Van Itallie et al., 2009a) via the leak pathway of trans-TJ flux (Anderson and Van Itallie, 2009; Turner, 2009; Weber et al., 2010). In contrast, conductance across the size- and charge-selective TJ paracellular pore pathway appears to be regulated by claudin proteins (Simon et al., 1999; Tsukita and Furuse, 2000; Van Itallie et al., 2008b; Anderson and Van Itallie, 2009; Rosenthal et al., 2010). The charge selectivity of these pores is determined by specific residues within the first extracellular loop of claudins (Balda et al., 2000; Furuse et al., 2001; Amasheh et al., 2002; Colegio et al., 2002, 2003; Van Itallie et al., 2003). For instance, paracellular pores created by claudin-2 allow small cations and water to pass, but exclude anions and larger solutes (Amasheh et al., 2002; Van Itallie et al., 2008b; Yu et al., 2009; Muto et al., 2010; Rosenthal et al., 2010). These pores appear to primarily be regulated by claudin-2 protein expression and half-life (Van Itallie et al., 2004; Heller et al., 2005; Weber et al., 2010) and, perhaps, by competition with other claudin family members (Van Itallie et al., 2001; Angelow et al., 2007). Although mathematical models of TJ barrier properties suggest that intra-TJ pores have defined open probabilities (Claude and Goodenough, 1973; Claude, 1978), neither the value nor regulation of this biophysical parameter has been determined.

The role of occludin in paracellular barrier function remains controversial (Saitou et al., 2000; Schulzke et al., 2005; Yu et al., 2005; Marchiando et al., 2010; Van Itallie et al., 2010), but hyperphosphorylation of the C-terminal cytoplasmic tail is associated with localization at TJs (Sakakibara et al., 1997; Wong, 1997). Several studies have assessed specific phosphorylated residues within occludin, and the region proximal to the C-terminal coiled-coil occludin/ELL (OCEL) domain appears to be a hotspot for functionally relevant sites. For example, T403 and T404 phosphorylation enhance both occludin trafficking to the TJ and paracellular barrier function (Suzuki et al., 2009). In contrast, phosphorylation of Y398 and Y402 reduces occludin–ZO-1 interactions, interferes with occludin localization at the TJ, and sensitizes monolayers to oxidant-induced barrier disruption (Elias et al., 2009). Similarly, phosphorylation of the more distal S490, which is located within the OCEL domain, attenuates the interaction between occludin and ZO-1 (Sundstrom et al., 2009) and is associated with occludin endocytosis and barrier loss (Murakami et al., 2009). Thus, although hyperphosphorylation is associated with occludin trafficking to the TJ, the impact of phosphorylation at specific sites within the C-terminal cytoplasmic tail is highly variable and may, at least in part, reflect modulation of ZO-1 binding.

The kinase CK2 (Litchfield et al., 2001; Meggio and Pinna, 2003) is known to phosphorylate occludin S408, T404, and, to a lesser extent, T400 in vitro and in vivo (Cordenonsi et al., 1999; Smales et al., 2003; Dörfel et al., 2009). Although the functional significance of CK2-mediated occludin phosphorylation has not been explored, S408 phosphorylation facilitates subsequent CK2-mediated phosphorylation at T404 and T400. This suggests that S408 phosphorylation is the rate-limiting step in CK2-mediated occludin phosphorylation (Dörfel et al., 2009). We therefore sought to determine the molecular and functional consequences of S408 occludin phosphorylation. The data indicate that S408 dephosphorylation reduces paracellular cation flux by stabilizing occludin–ZO-1 interactions that, in a ZO-1–dependent manner, enhance claudin-1 and claudin-2, but not claudin-4, exchange and prevent pore assembly or opening. Conversely, S408 phosphorylation enhances homotypic occludin–occludin interactions, releases ZO-1, and promotes paracellular cation flux via claudin-1– and claudin-2–based pores. We conclude that occludin S408 is a molecular switch by which CK2, and, potentially other occludin kinases, regulate TJ molecular remodeling, protein interactions, and paracellular pore function.

Results

CK2 decreases epithelial barrier function by amplifying paracellular ion flux

To determine if CK2 can regulate epithelial barrier function, polarized Caco-2 human intestinal epithelial cells were treated with the CK2 inhibitors 4,5,6,7-tetrabromobenzotriazole (TBB; IC50 1 µM; Sarno et al., 2001), 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT; IC50 0.15 µM; Pagano et al., 2004), and tetrabromocinnamic acid (TBCA; IC50 0.11 µM; Pagano et al., 2007). Each significantly elevated transepithelial electrical resistance (TER) in a dose-dependent manner that correlated with drug potency (Fig. 1 A). Peak TER increases were achieved within 3 h and were sustained for at least three additional hours of treatment (Fig. 1 B).

Figure 1.
CK2 decreases epithelial barrier function by amplifying paracellular ion flux. (A) CK2 inhibitors elevated Caco-2 TER in a dose-dependent manner after 5 h of treatment. (B) CK2 inhibition caused maximal TER increases within 3 h. (C) Chemical inhibition ...

Although the prolonged interval over which CK2 inhibition raises TER could allow protein synthesis or degradation, expression of ZO-1, claudin-1, claudin-2, or claudin-4, and the TJ-associated MARVEL proteins (TAMPs) occludin, tricellulin, and marvelD3, was unaffected (Fig. S1 A). Expression of these proteins was also unaffected by siRNA-mediated CK2 knockdown (Fig. S1, A–C), which increased TER to an extent comparable to enzymatic inhibition. Moreover, CK2 knockdown abrogated the ability of CK2 inhibitors to elevate TER (Fig. 1 C). Thus, the observed TER regulation is a function of CK2 inhibition, rather than off-target drug effects. Moreover, although previous studies have shown that CK2 can stimulate Na+/H+ exchanger 3 (NHE3; Sarker et al., 2008), which in turn can regulate TER (Turner et al., 2000), the effects of CK2 and NHE3 inhibition were additive (Fig. S1 D). Thus, the effect of CK2 inhibition on barrier function is independent of NHE3.

The 22 ± 1% increase in TER induced by 50 µM TBCA was accompanied by a 20 ± 1% decrease in paracellular Na+ flux, but TJ permeability to cations with radii larger than ~2.5 Å (Fig. 1 D), anions (not depicted), and uncharged macromolecules (Fig. S1 E) was unaffected. Therefore, CK2 regulates paracellular permeability of small cations through the pore pathway but does not affect leak pathway flux (Anderson and Van Itallie, 2009; Van Itallie et al., 2009b; Yu et al., 2009; Weber et al., 2010; Shen et al., 2011).

CK2-mediated barrier regulation is occludin dependent

Barrier regulation is commonly associated with TJ protein redistribution. Localizations of ZO-1, claudin-1, claudin-2, claudin-4, marvelD3, tricellulin, and occludin were therefore evaluated before and after CK2 inhibition. Only occludin distribution was affected (Fig. 2 A). CK2 inhibition increased TJ-associated occludin and decreased the number of occludin-containing cytoplasmic vesicles (Fig. 2, B and C). In contrast, CK2, which localizes to the cytoplasm, lateral membrane, and TJ of Caco-2 cells, was not redistributed after enzymatic inhibition (Fig. S1 F). Thus, barrier function increases after CK2 inhibition are associated with occludin redistribution to the TJ. Conversely, occludin removal from the TJ promotes barrier loss (Clayburgh et al., 2005; Shen and Turner, 2005; Murakami et al., 2009; Marchiando et al., 2010; Van Itallie et al., 2010). This suggests that TER regulation by CK2 may require occludin. To assess this, Caco-2 cells in which occludin expression was stably knocked down were developed. Occludin knockdown monolayers did not increase TER regulation after CK2 inhibition (Fig. 2 D), indicating an essential role of occludin in this form of barrier regulation. However, NHE3 inhibition increased TER of monolayers lacking occludin (Fig. S1 G), demonstrating that occludin knockdown monolayers are capable of barrier regulation and providing further evidence that the observed effects of CK2 inhibition are not related to NHE3. Thus, CK2 regulates TJ barrier function in an occludin-dependent manner.

Figure 2.
CK2-mediated barrier regulation is occludin dependent. (A) Effect of CK2 inhibition (50 µM DMAT) on distribution of transmembrane TJ proteins (green) and ZO-1 (red). Bar, 10 µm. (B) Quantitative analysis of occludin enrichment at the TJ. ...

CK2 inhibition stabilizes occludin, but not other TAMPs, at the TJ

To determine if CK2-dependent barrier regulation is associated with alterations in TJ protein dynamic behavior, FRAP was used to assess exchange of occludin and the related TAMPs tricellulin, marvelD3 variant 1, and marvelD3 variant 2 (Raleigh et al., 2010). The occludin mobile fraction was reduced from 71 ± 4% to 50 ± 4% (P < 0.01) after CK2 inhibition (Fig. 3, A and B).In contrast, mobile fractions of tricellulin or either marvelD3 splice variant were unaffected (Fig. 3, A and B). CK2 knockdown both reduced the occludin mobile fraction and rendered occludin recovery resistant to pharmacological CK2 inhibition (Fig. 3 C; Fig. S2 A; Table I). Thus, CK2 inhibition increases both the quantity and stability of TJ-associated occludin while increasing barrier function. Together, these data suggest that occludin recruitment and stabilization may be involved in the observed barrier regulation.

Table I.
The dynamic behavior of TJ components involved in CK2-mediated epithelial barrier regulation
Figure 3.
CK2 inhibition stabilizes occludin at the TJ in vitro and in vivo. (A) Kymographs of EGFP-TAMP FRAP, with or with out DMAT treatment (50 µM) at bicellular TJ regions. Bar, 3 µm. (B) Effect of CK2 inhibition (50 µM DMAT) on EGFP-TAMP ...

CK2 inhibition stabilizes occludin at the TJ in vivo

To determine if the effect of CK2 inhibition on occludin dynamic behavior in cell culture is an accurate recapitulation of in vivo biology, FRAP was performed using transgenic mice expressing EGFP-occludin under control of the villin promoter (Marchiando et al., 2010). CK2 inhibition significantly decreased the mobile fraction of occludin, from 57 ± 2% to 39 ± 1%, in vivo (P < 0.01) without altering the t1/2 of recovery or TJ protein expression (Fig. 3 D; Fig. S2, B–D). Thus, CK2 inhibition stabilizes occludin at the TJ in vivo in a manner similar to that observed in vitro. Notably, the failure of CK2 inhibition to affect paracellular flux of water or BSA in vivo (Fig. S2 E) is consistent with the in vitro data showing that CK2 affects size-selective barrier regulation and that NHE3 is not involved in this process.

Phosphorylation at S408 is required for CK2-mediated occludin regulation

To identify the residue(s) responsible for CK2 regulation of barrier function and occludin exchange, alanine (A) or aspartic acid (D) mutations were introduced at T404 and S408, the two primary sites of CK2-mediated occludin phosphorylation. EGFP-occludin mutants were expressed in occludin knockdown Caco-2 cells to avoid potential interactions with endogenous wild-type occludin and were efficiently trafficked to TJs. Similar to endogenous occludin, wild-type EGFP-occludin was enriched at the TJ after CK2 inhibition (Fig. S3, A and B). The mobile fractions of T404D/S408D, T404A, and S408D mutants were indistinguishable from that of wild-type EGFP-occludin at baseline (68 ± 4%, 68 ± 8%, 69 ± 3%, and 70 ± 4%, respectively; Fig. 4, A and B). In contrast, the mobile fractions of EGFP-occludin T404A/S408A and S408A were significantly reduced (52 ± 3% and 49 ± 3%, respectively), and were similar to those of wild-type and T404A EGFP-occludin after CK2 inhibition (47 ± 2% and 45 ± 4%, respectively). Moreover, FRAP behavior of occludin T404D/S408D, T404A/S408A, S408A, and S408D mutants was unaffected by CK2 inhibition (Fig. 4, A and B; Table I). Thus, S408, but not T404, is critical to occludin exchange at the TJ. S408 is also the key regulator of occludin trafficking, as EGFP-occludin S408A was enriched at the TJ relative to wild-type or S408D EGFP-occludin and neither S408A nor S408D mutants were redistributed after CK2 inhibition (Fig. S3, A and B).

Figure 4.
S408 phosphorylation is required for CK2-mediated regulation of occludin dynamics and barrier function. (A and B) FRAP analysis of EGFP-occludin mutants expressed in occludin knockdown Caco-2 cells. Bar, 3 µm. (C) Expression of EGFP or EGFP-occludin ...

Occludin phosphorylation at S408 is required for CK2-mediated barrier regulation

The effect of S408 mutations on FRAP behavior and TJ localization suggests that this residue may also be essential for CK2-mediated barrier regulation. To test this hypothesis, we measured the effect of CK2 inhibition on TER of wild-type or occludin knockdown Caco-2 monolayers as well as on TER of knockdown cell lines stably expressing wild-type or mutant EGFP-occludin. Neither occludin knockdown nor expression of EGFP-occludin constructs altered expression of endogenous TJ proteins or CK2 (Fig. S3 C). However, occludin knockdown did reduce steady-state TER (Fig. S3 D). Expression of EGFP-tagged wild-type and T404A occludin, but not EGFP alone, restored TER responses to CK2 inhibition (Fig. 4 C). In contrast, neither T404D/S408D nor S408A EGFP-occludin–expressing monolayers were sensitive to CK2 inhibition. Therefore, both occludin expression and phosphorylation at S408 are necessary for CK2-mediated barrier regulation. Moreover, the parallel roles of S408 in occludin trafficking and exchange as well as barrier regulation suggests that these processes are linked.

Occludin S408 dephosphorylation enhances interactions with claudin-1, claudin-2, and ZO-1

S408 is located within a structurally disordered region of the cytoplasmic C-terminal tail of human occludin (Li et al., 2005; Walter et al., 2009). This site is adjacent to C409, which is critical for occludin dimerization (Li et al., 2005; Walter et al., 2009), and suggests that that S408 phosphorylation may modify occludin association with other proteins. To explore this hypothesis, GST-fusion constructs of wild-type occludin 383–522 or mutants with either S408D or S408A substitutions were expressed as recombinant proteins and immobilized on glutathione-agarose. These were used to probe Caco-2 lysates, and captured proteins were analyzed by immunoblot. Consistent with a role for S408 in regulation of occludin dimerization, the S408D occludin tail captured 2.4 ± 0.05-fold more endogenous occludin than the S408A tail (Fig. 5 A; P < 0.05). In contrast, the S408A tail recovered claudin-1 and claudin-2 more efficiently, and captured 5.1 ± 1.3 (P < 0.01) and 2.8 ± 0.3-fold (P < 0.01) more of each, respectively, relative to the S408D tail. These differences were specific to claudin-1 and claudin-2, as similar amounts of marvelD3 and claudin-4 were captured by the three occludin tail constructs, and GST alone failed to recover any of these proteins (Fig. 5 A).

Figure 5.
Occludin S408 dephosphorylation enhances interactions with claudin-1, claudin-2, and ZO-1, and their exchange at the TJ. (A) GST-occludin C-terminal tails (383–522) immobilized on glutathione-agarose were used to probe Caco-2 lysates, and recovered ...

The occludin cytoplasmic tail has not been reported to interact directly with claudins. However, ZO-1 interacts with both occludin and claudins (Furuse et al., 1994; Itoh et al., 1999a; Nusrat et al., 2000; Schmidt et al., 2001). Thus, ZO-1 may serve as an intermediate in occludin–claudin-1/claudin-2 interactions that are regulated by S408 phosphorylation. To assess direct interactions between ZO-1 and occludin, binding of recombinant VSV G epitope-tagged ZO-1 U5-GuK domain (Kreis, 1986; Raleigh et al., 2010) to immobilized GST-occludin 383–522 S408D and S408A was assessed. Both GST-occludin tails, but not GST alone, bound to ZO-1 U5-GuK (Fig. 5 B). However, binding to the S408A tail was 3.2 ± 0.3-fold greater than to the S408D mutant (P < 0.01). These results suggest that interactions between occludin and ZO-1 are weakened by S408 phosphorylation. Together with the enhanced capture of full-length, endogenous occludin by the S408D occludin tail, these data also support the hypothesis that S408 phosphorylation acts as a molecular switch that determines whether occludin forms homodimers or heterotypic interactions with ZO-1.

The enhanced association of the ZO-1 U5-GuK construct with S408A occludin tail is consistent with a model where ZO-1 mediates interactions between occludin and claudin-1 or claudin-2. To determine if ZO-1 is required for claudin capture by immobilized GST-occludin 383–522, lysates of ZO-1 knockdown Caco-2 cells were probed with immobilized S408A and S408D occludin tails. ZO-1 knockdown almost completely eliminated claudin-2 recovery, and there was no difference between amounts captured by S408A and S408D occludin tails (Fig. 5 C). Thus, ZO-1 mediates S408 phosphorylation-regulated occludin interactions with claudin-2. Importantly, ZO-1 knockdown did not affect expression of ZO-2, or claudins 1, 2, or 4 (Fig. S4 A).

Occludin S408 dephosphorylation increases claudin-1, claudin-2, and ZO-1 exchange at the TJ

The studies above used cell lysates and recombinant proteins to show that S408 phosphorylation reduces interactions between occludin, ZO-1, claudin-1, and claudin-2. However, the large number of protein interactions at TJs may allow larger complexes to form within intact epithelial monolayers and make S408 phosphorylation irrelevant. Thus, as an indirect measure of protein interactions, mobile fractions were assessed by FRAP in confluent Caco-2 monolayers. Pharmacological CK2 inhibition in wild-type monolayers increased the mobile fraction of TJ-associated mRFP1-ZO-1 from 48 ± 3% to 60 ± 4% (Fig. 5 D; P < 0.05) but did not affect ZO-1 exchange in occludin knockdown monolayers. Moreover, S408A, but not wild-type or S408D EGFP-occludin increased mRFP1-ZO-1 exchange in a manner similar to CK2 inhibition (Fig. 5 D; P < 0.05). Thus, occludin S408 dephosphorylation enhances ZO-1 exchange at the TJ.

Based on the in vitro binding studies, the effects of wild-type, S408D, and S408A EGFP-occludin expression on mRFP1-claudin exchange were assessed. S408A EGFP-occludin expression markedly increased the mobile fractions of both mRFP1–claudin-1 and claudin-2 (Fig. 5 E); CK2 inhibition had a similar effect on mRFP1–claudin-2 exchange (Fig. 5 F). In contrast, FRAP behavior of mRFP1–claudin-4 was comparable in occludin knockdown monolayers and those expressing wild-type, S408D, or S408A EGFP-occludin (Fig. 5 E). Thus, in a manner that parallels the protein binding assay data, occludin S408 dephosphorylation affects exchange of claudin-1 and claudin-2, but not claudin-4.

To determine whether the observed increase in claudin-2 exchange requires occludin or ZO-1, mRFP1–claudin-2 FRAP was assessed in wild-type, occludin knockdown, and ZO-1 knockdown monolayers. Although pharmacological CK2 inhibition increased mRFP1–claudin-2 exchange in wild-type monolayers, the mRFP1–claudin-2 mobile fraction was unchanged in occludin or ZO-1 knockdown monolayers (Fig. 5 F). Thus, similar to the binding assays, the FRAP studies indicate that ZO-1 is required for the effects of occludin S408 dephosphorylation on claudin-2 exchange.

The data support the hypothesis that ZO-1 acts as a scaffold that links occludin to claudin-2. The sites within ZO-1 that mediate binding to claudins (PDZ1) and occludin (U5-GuK) are well defined (Fanning et al., 1998, 2007; Itoh et al., 1999a; Schmidt et al., 2004; Li et al., 2005; Müller et al., 2005; Umeda et al., 2006). To assess the roles of these ZO-1 domains in regulation of claudin-2 exchange, ZO-1 knockdown Caco-2 cells were cotransfected with mRFP1–claudin-2 and either wild-type, ΔPDZ1, or ΔU5-GuK EGFP-ZO-1. Wild-type EGFP–ZO-1 restored sensitivity of mRFP1–claudin-2 recovery to CK2 inhibition. In contrast, EGFP–ZO-1 lacking either the PDZ1 or U5-GuK domain failed to restore sensitivity of mRFP1–claudin-2 recovery to CK2 inhibition (Fig. 5 F).

When taken together with the in vitro binding assays, the FRAP studies of confluent monolayers suggest that physical interactions among occludin, ZO-1, and select claudins are facilitated by occludin S408 dephosphorylation. Consistent with this, the markedly different occludin, ZO-1, and claudin-2 mobile fractions of 68 ± 3%, 48 ± 3%, and 33 ± 3%, respectively, converge to 52 ± 5%, 60 ± 4%, and 51 ± 5%, respectively, after CK2 inhibition (Table II). Moreover, (a) the mobile fraction of wild-type occludin after CK2 inhibition is similar to that of EGFP-occludin S408A; (b) FRAP behaviors of wild-type, S408D, and S408A EGFP-occludin are similar in ZO-1 knockdown cells (Fig. 5 G); and (c) S408A occludin expression increases ZO-1, claudin-1, and claudin-2 exchange in a manner similar to CK2 inhibition (Table II). These data are all consistent with the hypothesis that occludin S408 dephosphorylation promotes assembly of protein complexes that include occludin, ZO-1, claudin-1, and claudin-2.

Table II.
CK2-mediated regulation of occludin, claudin-1, claudin-2, and ZO-1 mobile fractions

Previous analyses have shown that fluorescent recovery of occludin and ZO-1 occur by diffusion within the plasma membrane and exchange with cytosolic pools, respectively (Shen et al., 2008). Thus, if occludin S408 dephosphorylation does promote complex assembly, the mechanism of ZO-1 recovery would be expected to change to include a component due to intramembrane diffusion. Although multiple approaches can be used, intramembrane diffusion and cytosolic exchange are most readily distinguished by analysis of FRAP over extended TJ regions (Shen et al., 2008). As reported previously in MDCK cells (Shen et al., 2008), EGFP–ZO-1 recovery in control Caco-2 cells was uniform over the bleached region, consistent with cytosolic exchange (Fig. 5 H). In contrast, EGFP–ZO-1 recovery at the periphery of bleached regions was significantly increased after CK2 inhibition (Table I; P < 0.05), whereas recovery at the center of bleached regions was unchanged (Fig. 5 H). Thus, the observed increases in ZO-1 mobile fraction are due to enhanced recovery at the edges in a pattern typical of intramembranous diffusion. These data support the hypothesis that S408 dephosphorylation enhances occludin association with ZO-1 in living cells.

CK2-mediated barrier regulation requires ZO-1, claudin-1, and claudin-2

Together with reports that claudin-2 creates a small cation-selective paracellular pore (Amasheh et al., 2002; Van Itallie et al., 2008b; Yu et al., 2009), the increased claudin-2 mobile fraction and decreased paracellular cation permeability induced by CK2 inhibition suggest that the S408 dephosphorylation may disrupt assembly or opening of claudin-2 pores. This would directly link occludin dynamic behavior to TJ barrier function and suggest that the effects of CK2 inhibition on cation-selective paracellular flux may require occludin, ZO-1, and claudin-2. Consistent with this, CK2 inhibition induced dose-dependent TER increases and Na+ selectivity decreases in control, but not occludin knockdown, monolayers (Fig. 6, A and B). Thus, although occludin is not thought to form paracellular pores, it is required for regulation of paracellular Na+ conductance and barrier function after CK2 inhibition. Similarly, ZO-1 knockdown eliminated TER and Na+ selectivity responses to CK2 inhibition (Fig. 6, C and D). Thus, consistent with the in vitro binding and FRAP data, ZO-1 is also required for CK2-mediated regulation of paracellular cation pores.

Figure 6.
CK2-mediated barrier regulation requires ZO-1 and claudin-2. (A and B) TER and PNa+/PCl responses of control and occludin knockdown monolayers to CK2 inhibition. (C and D) TER and PNa+/PCl responses of control and ZO-1 knockdown monolayers ...

Both biochemical and FRAP data suggest that roles of occludin and ZO-1 in CK2-mediated barrier regulation are, primarily, to control claudin-2 function. This is also consistent with the observation that CK2 inhibition regulates paracellular flux of small cations that are characteristic of claudin-2–based pores. To directly assess the participation of claudin-2 in CK2-mediated barrier regulation, stable claudin-2 knockdown Caco-2 cells were developed (Fig. S4 B). As expected, claudin-2 knockdown markedly increased TER (Fig. 6 E), reduced Na+ selectivity (Fig. 6 E), and reduced paracellular permeability to cations smaller than ~2.5 Å (Fig. S4 C). In addition, claudin-2 knockdown monolayers displayed only limited TER increases (Fig. 6 F) and no change in Na+ selectivity (Fig. 6 G) after CK2 inhibition. The small size of the TER increases was not due to global disruption of barrier regulatory mechanisms, as claudin-2 knockdown monolayers remained sensitive to myosin light chain kinase inhibition (Fig. S4 D). Therefore, in a manner that parallels FRAP and in vitro binding data, claudin-2 is required for CK2-mediated regulation of paracellular cation permeability.

The effect of CK2 inhibition on TER was markedly reduced by claudin-2 knockdown. Nevertheless, a slight, although statistically significant, increase in TER was induced by 50 µM TBCA (Fig. 6 F). This could reflect off-target effects of TBCA at higher doses, such as GSK3 inhibition (Pagano et al., 2007). However, the observations that occludin or ZO-1 knockdown completely blocked the effects of TBCA, even at 50 µM (Fig. 6, A–D), argue against this explanation. Given that claudin-1 recovery and FRAP behavior are also modulated by S408 dephosphorylation, it was reasonable to hypothesize that claudin-1 could be responsible for the residual effects of 50 µM TBCA on TER of claudin-2 knockdown monolayers. Transient claudin-1 knockdown (Fig. S4 E) increased baseline TER, but to a much smaller degree than claudin-2 knockdown (Fig. 6 E), suggesting that claudin-1 enhances paracellular permeability. However, claudin-1 knockdown in cells lacking claudin-2 reduced TER, relative to claudin-2 knockdown alone, suggesting that claudin-1 may enhance barrier function in some contexts. Thus, claudin-1 may have both pore-forming and barrier-sealing functions. Although further study is required, this interpretation could be consistent with diverse but poorly defined claudin-1 functions in enhancing barrier function of MDCK monolayers, endothelial monolayers, and mouse skin (Inai et al., 1999; Furuse et al., 2002; Fujibe et al., 2004), as well as preventing congenital liver and skin disease in human patients (Hadj-Rabia et al., 2004).

Much like claudin-2 knockdown, claudin-1 knockdown reduced, but did not eliminate TER increases after CK2 inhibition (Fig. 6 H). However, combined claudin-1 and claudin-2 knockdown completely prevented TER increases induced by CK2 inhibition (Fig. 6 H). In contrast, claudin-1 knockdown did not prevent CK2 inhibitor-induced PNa+/PCl decreases, and charge selectivity responses of claudin-1/claudin-2 double knockdown monolayers were indistinguishable from those with only claudin-2 knockdown (Fig. 6 I). These data suggest that although claudin-1 contributes to CK2-mediated TER regulation, it participates by a mechanism that is distinct from claudin-2–dependent modulation of paracellular Na+ pathway permeability.

CK2 inhibition corrects pathophysiologic barrier dysfunction

Claudin-2 expression is markedly up-regulated in inflammatory bowel disease (Heller et al., 2005; Prasad et al., 2005; Holmes et al., 2006), likely as a result of IL-13 signaling (Heller et al., 2005; Prasad et al., 2005; Fichtner-Feigl et al., 2006, 2008). This can be reproduced in vitro (Heller et al., 2005; Weber et al., 2010), but the effect is limited in Caco-2 monolayers, which express claudin-2 constitutively. In contrast, T84 intestinal epithelial cells normally possess little claudin-2, but IL-13 markedly up-regulates claudin-2 expression to reduce TER and increase PNa+/PCl (Prasad et al., 2005; Weber et al., 2010). To determine if CK2 inhibition could correct IL-13–induced barrier dysfunction, T84 cells were treated with IL-13 to induce a 3.0 ± 0.2-fold increase in claudin-2 expression (Fig. 6 J), 23 ± 2% reduction in TER (Fig. 6 K), and 58 ± 11% increase in PNa+/PCl (Fig. 6 L). Remarkably, subsequent CK2 inhibition completely reversed IL-13–induced TER loss (Fig. 6 K) and PNa+/PCl increase (Fig. 6 L). Thus, CK2 inhibition can acutely reverse IL-13–induced barrier dysfunction and CK2 may be an attractive target for future pharmacological modulation of pathophysiological barrier defects.

Discussion

Despite a multitude of described interactions between TJ proteins, little information is available for understanding the means by which separate TJ components work together to regulate barrier function. Thus, identification of the molecular mechanisms that underlie TJ regulation is a major challenge that must be addressed during the next phase of TJ discovery. To begin to explore these processes, we assessed the effect of occludin phosphorylation on TJ molecular structure and barrier function. We focused on CK2, which acts as an occludin kinase in vivo and in vitro (Cordenonsi et al., 1997, 1999; Smales et al., 2003; Dörfel et al., 2009), but has not been associated with TJ regulation. The data show that CK2-mediated phosphorylation of occludin S408 modulates interactions between occludin, ZO-1, claudin-1, and claudin-2, and implicate S408 phosphorylation as a molecular switch that regulates TJ structure and paracellular pore pathway flux.

A model of CK2-mediated, occludin S408 phosphorylation-dependent barrier regulation

The data presented here show that CK2 inhibition reduces paracellular cation flux. This regulation requires occludin, and can be reproduced by S408A occludin expression without CK2 inhibition. ZO-1, claudin-1, and claudin-2 are also required for barrier regulation after CK2 inhibition, suggesting that occludin S408 dephosphorylation regulates claudin pore function via ZO-1 (Fig. 7). Thus, although we have focused on CK2, the phosphatase responsible for S408 dephosphorylation may also be important.

Figure 7.
Model of CK2-mediated regulation of TJ structure, dynamic behavior, and barrier function through occludin S408 phosphorylation. Proposed organization, interactions, and dynamic behavior of proteins involved in TJ regulation by CK2. (A) CK2-mediated phosphorylation ...

We used a combination of morphological and biochemical approaches to determine the mechanisms by which TJ proteins contribute to CK2-mediated barrier regulation. Morphometric analyses showed increased TJ localization of occludin after CK2 inhibition or S408A mutation. In binding assays, S408A occludin tail recovered more claudin-1 and claudin-2, but not claudin-4, from cell lysates, and also demonstrated enhanced ZO-1 binding, relative to a S408D mutant. Consistent with a role for ZO-1 as a scaffold, claudin-2 recovery from ZO-1 knockdown cell lysates was poor and similar for both occludin tails. Thus, static analyses of subcellular localization and in vitro binding suggest that S408 dephosphorylation promotes occludin trafficking to the TJ and physical association with ZO-1, claudin-1, and claudin-2.

Although a great deal has been learned from in vitro binding studies (Furuse et al., 1994; Itoh et al., 1997, 1999b; Fanning et al., 1998, 2002; Cordenonsi et al., 1999; Wittchen et al., 1999; Barritt et al., 2000; D’Atri and Citi, 2001; Meyer et al., 2002; Kale et al., 2003; Betanzos et al., 2004; Li et al., 2005; Müller et al., 2005; Seth et al., 2007; Van Itallie et al., 2008a), they do not provide information about dynamic interactions, are not generally used to measure protein interaction affinities, and cannot account for changes in protein structure or other regulatory events within live cells. We have therefore used mobile fraction as a measure of protein interactions in living cells. Although this is an indirect approach that has its own shortcomings, the combination of FRAP with in vitro binding data can be a powerful tool in analysis of protein interactions and function. Our studies show that both CK2 inhibition and S408A mutation reduce occludin mobile fraction, consistent with increased occludin localization at the TJ under these conditions. Although in vitro binding data show that occludin S408A mutation enhances occludin tail binding to ZO-1 and, via ZO-1, to claudin-1 and claudin-2, CK2 inhibition or S408A mutation increased mobile fractions of ZO-1 and these claudins. These data could be seen as contradictory, as one might presume that increased protein interactions should reduce the mobile fraction. However, this assumes that FRAP occurs entirely by diffusion, which is not the case (Shen et al., 2008). Here, the in vitro binding and FRAP data can be resolved by a model in which occludin dimers form more readily after S408 phosphorylation and are more mobile within the TJ, perhaps because they are not anchored by ZO-1, whereas binding of occludin and ZO-1 after S408 dephosphorylation disrupts interactions that anchor ZO-1 and, in turn, some claudins (Fig. 7). This will be an important issue to address in the future.

Previous studies have correlated overall occludin hyperphosphorylation with TJ localization (Sakakibara et al., 1997; Wong, 1997). Although correct at a global level (Seth et al., 2007), this is not necessarily true of specific phosphorylation sites within the C-terminal occludin tail. For example, phosphorylation of T403 and T404 facilitates trafficking to the epithelial TJ (Suzuki et al., 2009), whereas phosphorylation of Y398 and Y402 interferes with ZO-1 binding and TJ trafficking (Elias et al., 2009), and S490 phosphorylation results in ubiquitination, endocytosis, and downstream endothelial barrier loss (Murakami et al., 2009; Sundstrom et al., 2009). Thus, phosphorylation of specific sites within the occludin C-terminal tail may either enhance or diminish occludin TJ localization and barrier function. Our results show that S408 phosphorylation decreases occludin localization and stability at the TJ and also reduces interactions with ZO-1. Conversely, S408 dephosphorylation, or mutation to alanine, stabilizes and increases the amount of occludin at the TJ, enhances interactions with ZO-1, promotes association with claudin-1 and claudin-2, and reduces paracellular ion flux. However, ZO-1 is required for occludin stabilization, claudin binding, and barrier regulation after S408 dephosphorylation, suggesting that physical interactions between occludin and ZO-1 are critical mediators of these events. Interestingly, similar to myosin light chain kinase-dependent control of barrier function (Yu et al., 2010) and integrity (Van Itallie et al., 2009a), but in contrast to TJ assembly (McNeil et al., 2006; Shin and Margolis, 2006; Umeda et al., 2006), ZO-2 cannot substitute for ZO-1 in occludin S408-mediated TJ regulation.

Although changes in steady-state distributions were not detected, FRAP studies revealed increases in ZO-1, claudin-1, and claudin-2 mobile fractions after CK2 inhibition and S408A mutation. This resulted in convergence of occludin, ZO-1, claudin-1, and claudin-2 mobile fractions after occludin S408 dephosphorylation, and, for claudin-2, required that ZO-1 contain both PDZ1 and U5-GuK domains. Further, in vitro binding studies showed enhanced association of ZO-1, claudin-1, and claudin-2 with S408A, relative to S408D, occludin tail. As a whole, these data strongly support the idea that S408 dephosphorylation facilitates assembly of a protein complex to regulate molecular structure and barrier properties of the TJ.

In contrast to claudin-1 and claudin-2, neither in vitro binding nor FRAP analyses detected any changes in claudin-4 after S408 dephosphorylation. Thus, in addition to differences within the first extracellular loop that define charge selectivity (Van Itallie et al., 2001; Colegio et al., 2002), other structural features that determine functional differences between claudins remain to be discovered. These may include extracellular determinants of cis or trans interactions between claudins (Daugherty et al., 2007; Lim et al., 2008a,b; Piontek et al., 2008; Piehl et al., 2010). However, because at least some of the interactions described here must occur within the cytoplasm, intracellular claudin domains (Itoh et al., 1999a; Hamazaki et al., 2002; Van Itallie et al., 2004, 2005; Tanaka et al., 2005), e.g., the N-terminal tail, intracellular loop, or C-terminal tail, should also be considered.

Mechanisms by which occludin S408 serves as a molecular switch

The residues phosphorylated by CK2, including S408, are located immediately upstream of the OCEL domain that mediates occludin self-association, ZO-1 binding, and interactions with other proteins (Furuse et al., 1994; Fanning et al., 1998; Nusrat et al., 2000; Li et al., 2005; Blasig et al., 2006). Occludin residues 416–522 form three α-helices with a positively charged surface that binds ZO-1; replacement of these residues with aspartic acid abolishes both binding to ZO-1 and occludin trafficking to cell contacts (Li et al., 2005). The data reported here and those reported by others suggest that phosphorylation events just proximal to the OCEL domain regulate occludin–ZO-1 interactions and occludin trafficking (Kale et al., 2003; Elias et al., 2009; Murakami et al., 2009; Suzuki et al., 2009). Specifically, our studies indicate that S408 functions as a molecular switch that determines whether occludin forms homodimers or heterotypic interactions with ZO-1 and, therefore, suggest that S408 phosphorylation regulates coiled-coil domain structure. However, although crystal structure of recombinant occludin tails composed of residues 383–522 or 416–522 has been reported (Li et al., 2005), these constructs were not phosphorylated and there is no information available to describe the effect of phosphorylation events on coiled-coil domain structure. Nevertheless, it is interesting to note that both recombinant occludin tails behaved as monomers (Li et al., 2005), consistent with our hypothesis that dephosphorylation of S408 prevents occludin self-association.

Occludin regulates leak and pore pathway function

Both in vitro and in vivo studies suggest that occludin is not required for TJ assembly or development of barrier function (Saitou et al., 2000; Schulzke et al., 2005; Yu et al., 2005). This has led some to conclude that occludin is either a regulatory protein or is wholly unimportant to TJ function. Consistent with the former interpretation, occludin has been implicated in regulation of leak pathway flux of large macromolecules by studies of occludin knockdown, overexpression, or mutation in MDCK monolayers (Balda et al., 1996; Yu et al., 2005). Moreover, recent in vitro and in vivo work has demonstrated a critical role for occludin in cytokine-dependent leak pathway regulation (Marchiando et al., 2010; Van Itallie et al., 2010). Given that the occludin tail binds directly to ZO-1, but not claudins, this also agrees with recent data showing that ZO-1 is required for leak pathway regulation (Van Itallie et al., 2009a). Our observation that occludin phosphorylation modifies permeability of claudin-based pores was, therefore, unexpected. Thus, these new data add to the functions assigned to occludin and show that, beyond regulating the TJ leak pathway, occludin also contributes to control of pore pathway permeability.

Potential therapeutic utility of CK2 inhibition and occludin S408 dephosphorylation

Our observation that occludin regulates paracellular pore function by a mechanism that is, primarily, dependent on claudin-2, together with the near complete absence of claudin-2 expression in adult mouse intestine (Holmes et al., 2006), is consistent with essentially normal intestinal Na+ conductance and epithelial resistance reported in adult occludin knockout (Saitou et al., 2000; Schulzke et al., 2005) and adult, but not neonatal, claudin-2 knockout mice (Tamura et al., 2011). In addition, these data fit with the observations that CK2 inhibition reduces EGFP-occludin mobile fraction but does not affect paracellular flux of BSA, a leak pathway probe, or water in vivo. However, claudin-2 expression is known to be induced by mucosal immune activation in mice (Weber et al., 2010) and in human and experimental inflammatory bowel disease (Heller et al., 2005; Prasad et al., 2005; Zeissig et al., 2007; Weber et al., 2008, 2010). Our data show that, in this situation, CK2 inhibition reverses claudin-2–dependent increases in paracellular cation flux induced by IL-13, a key pathological mediator (Heller et al., 2002, 2005). Thus, although regulation of occludin S408 phosphorylation is not understood and would benefit from development of detection reagents, such as phosphospecific antibodies, it is tempting to speculate that CK2 inhibitors, several of which are being considered for clinical trials (Bortolato et al., 2008; Siddiqui-Jain et al., 2010), may be of therapeutic use in inflammatory bowel disease.

In conclusion, these data demonstrate that occludin S408 phosphorylation by CK2 acts as a molecular switch that regulates TJ protein interactions, molecular dynamics, and barrier function. In the absence of CK2 activity, occludin, ZO-1, and claudin-2 form a stable complex at the TJ. By phosphorylating S408, CK2 dissociates these proteins and facilitates cation flux across claudin-2–based pores. These results provide a new framework to understand the molecular interactions that regulate the TJ barrier in health and disease.

Materials and methods

Cell culture

Caco-2BBe cells were maintained in DME (4.5 g glucose/l) with 10% FCS and 15 mM Hepes, pH 7.4. Subconfluent, rapidly growing cultures were trypsinized and plated at confluence on collagen-coated, 0.4-µm pore size, polycarbonate membrane Transwells (Corning). Media was replenished thrice weekly, and monolayers were studied 14 d after confluence, unless otherwise specified (Turner et al., 1997). T84 cells were maintained in 1:1 F12/RPMI1640 media supplemented with 10% newborn calf serum and 15 mM Hepes, pH 7.4, as described previously (Weber et al., 2010). These were plated at confluence on Transwell membranes and studied after 10 d. CK2 inhibitors used were 4,5,6,7-tetrabromobenzotriazole (Sigma-Aldrich), 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (Sigma-Aldrich), and tetrabromocinnamic acid (EMD). All CK2 inhibitor stocks were made in DMSO. DMAT became unavailable and was replaced by TBCA in the course of this work. CK2 inhibitors and S3226 (Aventis Pharma) were added to both apical and basolateral media (Schwark et al., 1998). PIK was applied apically (Zolotarevsky et al., 2002). IL-13 (R&D Systems) was added basally as described previously (Weber et al., 2010).

Electrophysiology and barrier function

A standard current clamp (University of Iowa Bioengineering, Iowa City, IA) was used to measure transepithelial resistance (TER) of cultured monolayers, as described previously (Turner et al., 1997). TER of control Caco-2 monolayers ranged from 151 ± 6 to 255 ± 5 Ohms x cm2. All data shown are representative of ≥3 experiments, each in triplicate or greater. For stable transfectants, data are representative of ≥3 stable cell lines for each construct, each assayed in triplicate.

NaCl dilution potentials were measured similarly and ion selectivity was determined as described previously (Weber et al., 2010). Biionic potentials were measured by replacing basal Na, which has a radius of 0.95 Å, for organic cations with larger radii, specifically methylamine (1.9 Å), ethylamine (2.3 Å), tetramethylammonium (2.8 Å), tetraethylammonium (3.3 Å), or N-methyl-d-glucamine (3.7 Å) (Sigma-Aldrich). Absolute Na+ permeability (PNa) was calculated using the equation

PNa=RTF2×G[Na+]+PCLPNA[Cl],

where G is the overall monolayer conductance per unit surface area measured in symmetrical HBSS solutions, T is the absolute temperature, R is the gas constant, and F is Faraday’s constant (Kimizuka and Koketsu, 1964; Yu et al., 2009). From the value of PNa, and the known relative permeabilities to the other ions, the absolute permeabilities to those ions could then be deduced using the Goldman-Hodgkin-Katz equation. Liquid junction potentials, measured using cell-free Transwells, were <0.1 mV. All data shown are representative of ≥3 experiments, each in triplicate.

For flux of larger macromolecules, FITC (0.1 mg/ml), 3-kD FITC-dextran (1 mg/ml), and 10-kD FITC-dextran (2.5 mg/ml) conjugates (Invitrogen) were added to the apical chamber. Aliquots were removed from the basal chamber at 30-min intervals over 2 h, as described previously (Wang et al., 2005). All data shown are representative of ≥3 experiments, each in triplicate.

Gene knockdown

For transient CK2 knockdown, Caco-2BBe cells were cotransfected with pooled CK2α (5′-GCAUUUAGGUGGAGACUUC-3′, 5′-GGAAGUGUCUUAGUUAC-3′, 5′-GCUGGUCGCUUACAUCACU-3′, and 5′-AACAUUGUCUGUACAGGUU-3′) and CK2α’ (5′-GAGUUUGGGCUGUAUGUUA-3′, 5′-GGGACAACAUUCACGGAAA-3′, 5′-GAUAGAUCACCAACAGAAA-3′, and 5′-UUAAGCAACUCUACCAGAU-3′) targeting siRNA (Thermo Fisher Scientific). Transient claudin-1 knockdown used pooled claudin-1 (5′-GAGGAUGGCUGUCAUUGGG-3′, 5′-CACCAAGGCCCUAUCCAAA-3′, 5′-GGAAAGACUACGUGUGACA-3′, and 5′-GCAAUAGAAUCGUUCAAGA-3′) targeting siRNA (Thermo Fisher Scientific). All siRNA species were transfected using Lipfectamine 2000 (Invitrogen), as described previously (Hu et al., 2006), and controls were transfected with nontargeting pooled scrambled siRNAs with similar GC content. Monolayers were studied 7 d after confluence.

pSUPER (Oligoengine) containing the occludin targeting sequence 5′-GTGAAGAGTACATGGCTGC-3′ (Yu et al., 2005) was used to stably transfect Caco-2BBe cells stably expressing SGLT1 (Turner et al., 1997), which suppressed >90% of occludin expression. ZO-1 knockdown cells were generated similarly, as described previously (Yu et al., 2010). Claudin-2 knockdown was achieved by stably transfecting Caco-2BBe with pSUPER vector containing the targeting sequence 5′-GCTAAGGGCTATAGACAAT-3′. Controls for each were stably transfected with a pSUPER vector containing a related, but ineffective, sequence.

CK2 assay

CK2 activity was assessed in lysates of siRNA-treated Caco-2 cells as described previously (Ruzzene et al., 2010). In brief, 300 µg total cell protein was incubated with 0.1 mM CK2 substrate peptide (RRRADDSDDDDD) and 10 µM [32P]ATP for 10 min at 30°C in a total volume of 20 µl. Reactions were terminated by spotting onto phosphocellulose filters, which were then washed with 0.5% phosphoric acid. Because other kinases can phosphorylate the substrate peptide, all samples were assayed in the presence of vehicle or 0.5 µM TBCA; the TBCA-inhibitable activity was considered to represent CK2 activity.

Immunoblots

Caco-2BBe monolayers were scraped from Transwell supports and mouse jejunal enterocytes were isolated as described previously (Clayburgh et al., 2005; Raleigh et al., 2010). Cells were resuspended and lysed in reducing Laemmli sample buffer, and protein concentrations were determined. Equal quantities of protein were loaded into each lane for SDS-PAGE separation. Immunoblots were performed as described previously (Raleigh et al., 2010), using CK2α (BD), CK2α′ (Abcam), claudin-1, claudin-2, claudin-4, occludin, tricellulin, ZO-1, ZO-2, and GAPDH antibodies (Invitrogen), as well as anti-marvelD3 (Raleigh et al., 2010) polyclonal antisera, and anti-VSVG monoclonal antibodies (Kreis, 1986).

Immunofluorescent staining and microscopy

To preserve intracellular vesicles, monolayers were fixed at −20°C with methanol and then cross-linked with bis(sulfosuccinimidyl)suberate (Shen and Turner, 2005). Immunofluorescent staining used GFP, claudin-1, claudin-2, claudin-4, occludin, tricellulin, and ZO-1 antibodies (Invitrogen), as well as anti-marvelD3 (Raleigh et al., 2010) polyclonal antisera and CK2α antibodies (BD), followed by species-specific secondary antisera conjugated to Alexa Fluor 488 or Alexa Fluor 594 (Invitrogen). Images were collected using a DMLB epifluorescence microscope (Leica) equipped with an 88000 filter set (Chroma Technology Corp.), a 63x Plan Apochromat 1.32 NA oil immersion objective, Retiga EXi camera (QImaging), and controlled by MetaMorph 7. Z stacks were collected at 0.2-µm intervals, and deconvolved with Autodeblur X2 (Media Cybernetics) for 10 iterations, with low noise level, intensity correction, accelerated SA detection, minimal intensity removal, and dynamic subvoluming as described previously (Raleigh et al., 2010). All images shown are representative of ≥3 independent experiments, each with at least duplicate samples. For morphometric analyses, TJ intensity was calculated as the ratio of TJ to total cell fluorescence, using at least 30 cells from each of three independent experiments (for each treatment condition).

Fluorescent proteins

Fluorescent fusion constructs were generated as described previously (Campbell et al., 2002; Shen and Turner, 2005; Raleigh et al., 2010). Claudin-2 (I.M.A.G.E. clone 30322852) and claudin-4 (I.M.A.G.E. clone 3349211) cDNAs were purchased from American Type Culture Collection (Manassas, VA). Site-directed mutagenesis with the QuikChange XL kit (Agilent Technologies) was used to create serine to alanine, serine to aspartic acid, and silent siRNA-evading mutations within EGFP-occludin. Wild-type EGFP-ZO-1 with silent siRNA-evading mutations for reexpression in ZO-1 knockdown cells was generated by site-directed mutagenesis; amino acids 1–120 and 590–803 were eliminated to create EGFP-ZO-1 ΔPDZ1 and ΔU5-GuK mutant constructs, respectively. Sequencing and restriction digestion was used to confirm plasmid sequence and directionality.

FRAP

In vitro FRAP was performed after transfection of fluorescent constructs into Caco-2BBe cells as described previously (Raleigh et al., 2010; Yu et al., 2010), and, where indicated, after 3 h of treatment with either pharmacological CK2 inhibitors or vehicle. Monolayers were imaged in HBSS supplemented with drug or vehicle on a 37°C temperature-controlled stage. Fluorescence bleaching and imaging were performed using an epifluorescence microscope (model DM4000; Leica) with a MicroPoint system (Photonic Instruments), Coolsnap HQ camera (Roper Scientific), and 63x U-V-I 1.2 NA water immersion objective controlled by MetaMorph 7. Images were collected until steady-state fluorescence intensity was reached. All data shown are representative of ≥3 experiments, each with n = 4.

In vivo FRAP was performed after intestinal perfusion of DMAT or vehicle (see below), as described previously (Yu et al., 2010). EGFP-occludin was excited using a 488 argon ion laser mounted on an SP5 microscope (Leica) with a 40x 0.8 NA water immersion objective. Bleaching was performed with 476, 488, and 514 argon ion lasers, and images were collected until steady-state fluorescence intensity was reached. Data for in vivo FRAP data are displayed as the average of ≥40 bleach sites per mouse, with two mice studied for each condition.

Raw data were aligned and mean fluorescence of background, whole-field, and bleached regions were quantified over time using MetaMorph. Background fluorescence was subtracted from bleached regions and whole-field fluorescence at each time point. Bleached region and whole-field data were normalized to their respective prebleach intensities, and fluorescence recovery within bleached regions relative to whole-field intensity was plotted over time. Sigma Plot (SPSS Inc.) was used for curve fitting to f(x) = y0 + a(1 − e−bx). Mobile fraction and halftime of recovery were calculated as (a)/(1 − y0) and ln(2)/b, respectively. Neither occludin mutation nor CK2 inhibition altered t1/2 of recovery, in vitro or in vivo.

Animals

Experiments were performed using 7–10-wk-old C57BL/6 mice expressing EGFP-occludin under control of the villin promoter (Marchiando et al., 2010). All studies were conducted in an AAALAC accredited facility under protocols approved by The University of Chicago IACUC. For in vivo CK2 inhibition, mice were anaesthetized and a 5-cm loop of jejunum was exposed, cannulated, and flushed to remove luminal material. The jejunum was perfused with media containing DMAT or vehicle for 60 min before imaging as described previously (Marchiando et al., 2010). A similar approach was used to assess paracellular Alexa 488 BSA and water flux in vivo (Clayburgh et al., 2005; Marchiando et al., 2010).

GST pulldown

GST-occludin 383–522 wild-type, S408D, and S408A constructs were generated by site-directed mutagenesis of previously described GST-occludin C-terminal tail constructs (Raleigh et al., 2010). A VSV G epitope-tagged human ZO-1 U5-GuK domain construct consisting of residues 591–754 was generated by cloning cDNA into pGEX-4T3 (GE Healthcare) and removing the GST coding sequence by site-directed mutagenesis (Raleigh et al., 2010). BL21(DE3)pLysS-competent bacteria were transformed with GST- and VSV G–tagged constructs, induced with IPTG, and processed using a GST Protein Interaction Pulldown kit (Thermo Fisher Scientific) with RIPA buffer containing TBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.004% sodium azide, and protease and phosphatase inhibitors (Santa Cruz Biotechnology, Inc.). For pulldown from Caco-2BBe lysates, monolayers were washed once in 4°C TBS and incubated in RIPA buffer at 4°C for 30 min. Cells were passed five times through a 21-gauge needle, and clarified for 5 min at 12,000 rpm. Bacterial and Caco-2BBe supernatants were incubated with immobilized bait constructs at 4°C overnight with rocking, and, after three washes in 10 mM NaCl, eluted with 10 mM reduced glutathione. All data shown are representative of ≥2 experiments, each with at least duplicate samples.

Statistical analysis

All data are presented as mean ± SE unless otherwise specified. Student’s unpaired t test was used to compare means, with statistical significance taken as P < 0.05.

Online supplemental material

Fig. S1 shows that neither CK2 inhibition nor CK2 knockdown affect TJ protein expression, provides controls for CK2 knockdown, demonstrates that CK2 effects on NHE3 function do not play a role in the observed barrier regulation, assesses paracellular flux of larger uncharged molecules before and after CK2 inhibition, and evaluates intracellular CK2 distribution. Fig. S2 shows kymographs of EGFP-occludin in control and CK2 knockdown Caco-2 monolayers, images and kymographs of EGFP-occludin in mouse jejunal enterocytes in vivo, that CK2 inhibition does not affect TJ protein expression in mouse jejunal enterocytes, and that CK2 inhibition does not affect in vivo water transport or paracellular BSA flux in mouse jejunum. Fig. S3 shows redistribution of wild-type and mutant EGFP-occludin proteins in response to CK2 inhibition and provides protein expression and transepithelial resistance data for transfected Caco-2 monolayers. Fig. S4 shows protein expression after ZO-1, claudin-1, or claudin-2 knockdown, cation permeability of stable claudin-2 knockdown Caco-2 cell lines, and the TER response of claudin-2 knockdown cell lines to myosin light chain kinase inhibition. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.201010065/DC1.

Acknowledgments

We thank Lindsay Raleigh for support and encouragement; W. Vallen Graham, Andrew Hawk, Stephen C. Meredith, Adam Schmitt, and Alan Yu for generously sharing advice; and Juergen Puenter and Roger Tsien for providing essential reagents.

This work was supported by the National Institutes of Health grants R01DK61931, R01DK68271, P01DK67887, P30CA14599, P30DK042086, K08DK088953, T32HL007237, T32DK007074, and T32GM07281. L. Shen is supported by a Crohn’s and Colitis Foundation of America Career Development Award and was previously supported by a Crohn’s and Colitis Foundation of America Research Fellowship Award sponsored by Ms. Laura McAteer Hoffman.

Footnotes

Abbreviations used in this paper:

DMAT
2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole
EGFP
enhanced green fluorescent protein
FITC
fluorescein isothiocyanate
KD
knockdown
mRFP1
monomeric red fluorescent protein 1
TAMP
TJ-associated MARVEL protein
TBCA
tetrabromocinnamic acid
TER
transepithelial electrical resistance
TJ
tight junction

References

  • Amasheh S., Meiri N., Gitter A.H., Schöneberg T., Mankertz J., Schulzke J.D., Fromm M. 2002. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J. Cell Sci. 115:4969–4976 10.1242/jcs.00165 [PubMed] [Cross Ref]
  • Anderson J.M., Van Itallie C.M. 2009. Physiology and function of the tight junction. Cold Spring Harb. Perspect. Biol. 1:a002584 10.1101/cshperspect.a002584 [PMC free article] [PubMed] [Cross Ref]
  • Angelow S., Schneeberger E.E., Yu A.S. 2007. Claudin-8 expression in renal epithelial cells augments the paracellular barrier by replacing endogenous claudin-2. J. Membr. Biol. 215:147–159 10.1007/s00232-007-9014-3 [PubMed] [Cross Ref]
  • Balda M.S., Whitney J.A., Flores C., González S., Cereijido M., Matter K. 1996. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J. Cell Biol. 134:1031–1049 10.1083/jcb.134.4.1031 [PMC free article] [PubMed] [Cross Ref]
  • Balda M.S., Flores-Maldonado C., Cereijido M., Matter K. 2000. Multiple domains of occludin are involved in the regulation of paracellular permeability. J. Cell. Biochem. 78:85–96 10.1002/(SICI)1097-4644(20000701)78:1<85::AID-JCB8>3.0.CO;2-F [PubMed] [Cross Ref]
  • Barritt D.S., Pearn M.T., Zisch A.H., Lee S.S., Javier R.T., Pasquale E.B., Stallcup W.B. 2000. The multi-PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane-spanning proteoglycan NG2. J. Cell. Biochem. 79:213–224 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G [PMC free article] [PubMed] [Cross Ref]
  • Betanzos A., Huerta M., Lopez-Bayghen E., Azuara E., Amerena J., González-Mariscal L. 2004. The tight junction protein ZO-2 associates with Jun, Fos and C/EBP transcription factors in epithelial cells. Exp. Cell Res. 292:51–66 10.1016/j.yexcr.2003.08.007 [PubMed] [Cross Ref]
  • Blasig I.E., Winkler L., Lassowski B., Mueller S.L., Zuleger N., Krause E., Krause G., Gast K., Kolbe M., Piontek J. 2006. On the self-association potential of transmembrane tight junction proteins. Cell. Mol. Life Sci. 63:505–514 10.1007/s00018-005-5472-x [PubMed] [Cross Ref]
  • Bortolato A., Cozza G., Moro S. 2008. Protein kinase CK2 inhibitors: emerging anticancer therapeutic agents? Anticancer. Agents Med. Chem. 8:798–806 [PubMed]
  • Campbell R.E., Tour O., Palmer A.E., Steinbach P.A., Baird G.S., Zacharias D.A., Tsien R.Y. 2002. A monomeric red fluorescent protein. Proc. Natl. Acad. Sci. USA. 99:7877–7882 10.1073/pnas.082243699 [PubMed] [Cross Ref]
  • Claude P. 1978. Morphological factors influencing transepithelial permeability: a model for the resistance of the zonula occludens. J. Membr. Biol. 39:219–232 10.1007/BF01870332 [PubMed] [Cross Ref]
  • Claude P., Goodenough D.A. 1973. Fracture faces of zonulae occludentes from “tight” and “leaky” epithelia. J. Cell Biol. 58:390–400 10.1083/jcb.58.2.390 [PMC free article] [PubMed] [Cross Ref]
  • Clayburgh D.R., Barrett T.A., Tang Y., Meddings J.B., Van Eldik L.J., Watterson D.M., Clarke L.L., Mrsny R.J., Turner J.R. 2005. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J. Clin. Invest. 115:2702–2715 10.1172/JCI24970 [PMC free article] [PubMed] [Cross Ref]
  • Colegio O.R., Van Itallie C.M., McCrea H.J., Rahner C., Anderson J.M. 2002. Claudins create charge-selective channels in the paracellular pathway between epithelial cells. Am. J. Physiol. Cell Physiol. 283:C142–C147 [PubMed]
  • Colegio O.R., Van Itallie C., Rahner C., Anderson J.M. 2003. Claudin extracellular domains determine paracellular charge selectivity and resistance but not tight junction fibril architecture. Am. J. Physiol. Cell Physiol. 284:C1346–C1354 [PubMed]
  • Cordenonsi M., Mazzon E., De Rigo L., Baraldo S., Meggio F., Citi S. 1997. Occludin dephosphorylation in early development of Xenopus laevis. J. Cell Sci. 110:3131–3139 [PubMed]
  • Cordenonsi M., Turco F., D’atri F., Hammar E., Martinucci G., Meggio F., Citi S. 1999. Xenopus laevis occludin. Identification of in vitro phosphorylation sites by protein kinase CK2 and association with cingulin. Eur. J. Biochem. 264:374–384 10.1046/j.1432-1327.1999.00616.x [PubMed] [Cross Ref]
  • D’Atri F., Citi S. 2001. Cingulin interacts with F-actin in vitro. FEBS Lett. 507:21–24 10.1016/S0014-5793(01)02936-2 [PubMed] [Cross Ref]
  • Daugherty B.L., Ward C., Smith T., Ritzenthaler J.D., Koval M. 2007. Regulation of heterotypic claudin compatibility. J. Biol. Chem. 282:30005–30013 10.1074/jbc.M703547200 [PubMed] [Cross Ref]
  • Dörfel M.J., Westphal J.K., Huber O. 2009. Differential phosphorylation of occludin and tricellulin by CK2 and CK1. Ann. N. Y. Acad. Sci. 1165:69–73 10.1111/j.1749-6632.2009.04043.x [PubMed] [Cross Ref]
  • Elias B.C., Suzuki T., Seth A., Giorgianni F., Kale G., Shen L., Turner J.R., Naren A., Desiderio D.M., Rao R. 2009. Phosphorylation of Tyr-398 and Tyr-402 in occludin prevents its interaction with ZO-1 and destabilizes its assembly at the tight junctions. J. Biol. Chem. 284:1559–1569 10.1074/jbc.M804783200 [PMC free article] [PubMed] [Cross Ref]
  • Fanning A.S., Jameson B.J., Jesaitis L.A., Anderson J.M. 1998. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J. Biol. Chem. 273:29745–29753 10.1074/jbc.273.45.29745 [PubMed] [Cross Ref]
  • Fanning A.S., Ma T.Y., Anderson J.M. 2002. Isolation and functional characterization of the actin binding region in the tight junction protein ZO-1. FASEB J. 16:1835–1837 [PubMed]
  • Fanning A.S., Little B.P., Rahner C., Utepbergenov D., Walther Z., Anderson J.M. 2007. The unique-5 and -6 motifs of ZO-1 regulate tight junction strand localization and scaffolding properties. Mol. Biol. Cell. 18:721–731 10.1091/mbc.E06-08-0764 [PMC free article] [PubMed] [Cross Ref]
  • Fichtner-Feigl S., Strober W., Kawakami K., Puri R.K., Kitani A. 2006. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 12:99–106 10.1038/nm1332 [PubMed] [Cross Ref]
  • Fichtner-Feigl S., Young C.A., Kitani A., Geissler E.K., Schlitt H.J., Strober W. 2008. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology. 135:2003–2013: 2013: e1–e7 10.1053/j.gastro.2008.08.055 [PubMed] [Cross Ref]
  • Fujibe M., Chiba H., Kojima T., Soma T., Wada T., Yamashita T., Sawada N. 2004. Thr203 of claudin-1, a putative phosphorylation site for MAP kinase, is required to promote the barrier function of tight junctions. Exp. Cell Res. 295:36–47 10.1016/j.yexcr.2003.12.014 [PubMed] [Cross Ref]
  • Furuse M., Itoh M., Hirase T., Nagafuchi A., Yonemura S., Tsukita S., Tsukita S. 1994. Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J. Cell Biol. 127:1617–1626 10.1083/jcb.127.6.1617 [PMC free article] [PubMed] [Cross Ref]
  • Furuse M., Furuse K., Sasaki H., Tsukita S. 2001. Conversion of zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin-Darby canine kidney I cells. J. Cell Biol. 153:263–272 10.1083/jcb.153.2.263 [PMC free article] [PubMed] [Cross Ref]
  • Furuse M., Hata M., Furuse K., Yoshida Y., Haratake A., Sugitani Y., Noda T., Kubo A., Tsukita S. 2002. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J. Cell Biol. 156:1099–1111 10.1083/jcb.200110122 [PMC free article] [PubMed] [Cross Ref]
  • Hadj-Rabia S., Baala L., Vabres P., Hamel-Teillac D., Jacquemin E., Fabre M., Lyonnet S., De Prost Y., Munnich A., Hadchouel M., Smahi A. 2004. Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease. Gastroenterology. 127:1386–1390 10.1053/j.gastro.2004.07.022 [PubMed] [Cross Ref]
  • Hamazaki Y., Itoh M., Sasaki H., Furuse M., Tsukita S. 2002. Multi-PDZ domain protein 1 (MUPP1) is concentrated at tight junctions through its possible interaction with claudin-1 and junctional adhesion molecule. J. Biol. Chem. 277:455–461 10.1074/jbc.M109005200 [PubMed] [Cross Ref]
  • Heller F., Fuss I.J., Nieuwenhuis E.E., Blumberg R.S., Strober W. 2002. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 17:629–638 10.1016/S1074-7613(02)00453-3 [PubMed] [Cross Ref]
  • Heller F., Florian P., Bojarski C., Richter J., Christ M., Hillenbrand B., Mankertz J., Gitter A.H., Bürgel N., Fromm M., et al. 2005. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 129:550–564 [PubMed]
  • Holmes J.L., Van Itallie C.M., Rasmussen J.E., Anderson J.M. 2006. Claudin profiling in the mouse during postnatal intestinal development and along the gastrointestinal tract reveals complex expression patterns. Gene Expr. Patterns. 6:581–588 10.1016/j.modgep.2005.12.001 [PubMed] [Cross Ref]
  • Hu Z., Wang Y., Graham W.V., Su L., Musch M.W., Turner J.R. 2006. MAPKAPK-2 is a critical signaling intermediate in NHE3 activation following Na+-glucose cotransport. J. Biol. Chem. 281:24247–24253 10.1074/jbc.M602898200 [PubMed] [Cross Ref]
  • Inai T., Kobayashi J., Shibata Y. 1999. Claudin-1 contributes to the epithelial barrier function in MDCK cells. Eur. J. Cell Biol. 78:849–855 [PubMed]
  • Itoh M., Nagafuchi A., Moroi S., Tsukita S. 1997. Involvement of ZO-1 in cadherin-based cell adhesion through its direct binding to alpha catenin and actin filaments. J. Cell Biol. 138:181–192 10.1083/jcb.138.1.181 [PMC free article] [PubMed] [Cross Ref]
  • Itoh M., Furuse M., Morita K., Kubota K., Saitou M., Tsukita S. 1999a. Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. J. Cell Biol. 147:1351–1363 10.1083/jcb.147.6.1351 [PMC free article] [PubMed] [Cross Ref]
  • Itoh M., Morita K., Tsukita S. 1999b. Characterization of ZO-2 as a MAGUK family member associated with tight as well as adherens junctions with a binding affinity to occludin and alpha catenin. J. Biol. Chem. 274:5981–5986 10.1074/jbc.274.9.5981 [PubMed] [Cross Ref]
  • Kale G., Naren A.P., Sheth P., Rao R.K. 2003. Tyrosine phosphorylation of occludin attenuates its interactions with ZO-1, ZO-2, and ZO-3. Biochem. Biophys. Res. Commun. 302:324–329 10.1016/S0006-291X(03)00167-0 [PubMed] [Cross Ref]
  • Kimizuka H., Koketsu K. 1964. Ion transport through cell membrane. J. Theor. Biol. 6:290–305 10.1016/0022-5193(64)90035-9 [PubMed] [Cross Ref]
  • Kreis T.E. 1986. Microinjected antibodies against the cytoplasmic domain of vesicular stomatitis virus glycoprotein block its transport to the cell surface. EMBO J. 5:931–941 [PubMed]
  • Li Y., Fanning A.S., Anderson J.M., Lavie A. 2005. Structure of the conserved cytoplasmic C-terminal domain of occludin: identification of the ZO-1 binding surface. J. Mol. Biol. 352:151–164 10.1016/j.jmb.2005.07.017 [PubMed] [Cross Ref]
  • Lim T.S., Vedula S.R., Hunziker W., Lim C.T. 2008a. Kinetics of adhesion mediated by extracellular loops of claudin-2 as revealed by single-molecule force spectroscopy. J. Mol. Biol. 381:681–691 10.1016/j.jmb.2008.06.009 [PubMed] [Cross Ref]
  • Lim T.S., Vedula S.R., Kausalya P.J., Hunziker W., Lim C.T. 2008b. Single-molecular-level study of claudin-1-mediated adhesion. Langmuir. 24:490–495 10.1021/la702436x [PubMed] [Cross Ref]
  • Litchfield D.W., Bosc D.G., Canton D.A., Saulnier R.B., Vilk G., Zhang C. 2001. Functional specialization of CK2 isoforms and characterization of isoform-specific binding partners. Mol. Cell. Biochem. 227:21–29 10.1023/A:1013188101465 [PubMed] [Cross Ref]
  • Marchiando A.M., Shen L., Graham W.V., Weber C.R., Schwarz B.T., Austin J.R., II, Raleigh D.R., Guan Y., Watson A.J., Montrose M.H., Turner J.R. 2010. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J. Cell Biol. 189:111–126 10.1083/jcb.200902153 [PMC free article] [PubMed] [Cross Ref]
  • McNeil E., Capaldo C.T., Macara I.G. 2006. Zonula occludens-1 function in the assembly of tight junctions in Madin-Darby canine kidney epithelial cells. Mol. Biol. Cell. 17:1922–1932 10.1091/mbc.E05-07-0650 [PMC free article] [PubMed] [Cross Ref]
  • Meggio F., Pinna L.A. 2003. One-thousand-and-one substrates of protein kinase CK2? FASEB J. 17:349–368 10.1096/fj.02-0473rev [PubMed] [Cross Ref]
  • Meyer T.N., Schwesinger C., Denker B.M. 2002. Zonula occludens-1 is a scaffolding protein for signaling molecules. Galpha(12) directly binds to the Src homology 3 domain and regulates paracellular permeability in epithelial cells. J. Biol. Chem. 277:24855–24858 10.1074/jbc.C200240200 [PubMed] [Cross Ref]
  • Mitic L.L., Anderson J.M. 1998. Molecular architecture of tight junctions. Annu. Rev. Physiol. 60:121–142 10.1146/annurev.physiol.60.1.121 [PubMed] [Cross Ref]
  • Müller S.L., Portwich M., Schmidt A., Utepbergenov D.I., Huber O., Blasig I.E., Krause G. 2005. The tight junction protein occludin and the adherens junction protein alpha-catenin share a common interaction mechanism with ZO-1. J. Biol. Chem. 280:3747–3756 10.1074/jbc.M411365200 [PubMed] [Cross Ref]
  • Murakami T., Felinski E.A., Antonetti D.A. 2009. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J. Biol. Chem. 284:21036–21046 10.1074/jbc.M109.016766 [PMC free article] [PubMed] [Cross Ref]
  • Muto S., Hata M., Taniguchi J., Tsuruoka S., Moriwaki K., Saitou M., Furuse K., Sasaki H., Fujimura A., Imai M., et al. 2010. Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules. Proc. Natl. Acad. Sci. USA. 107:8011–8016 10.1073/pnas.0912901107 [PubMed] [Cross Ref]
  • Nusrat A., Chen J.A., Foley C.S., Liang T.W., Tom J., Cromwell M., Quan C., Mrsny R.J. 2000. The coiled-coil domain of occludin can act to organize structural and functional elements of the epithelial tight junction. J. Biol. Chem. 275:29816–29822 10.1074/jbc.M002450200 [PubMed] [Cross Ref]
  • Pagano M.A., Meggio F., Ruzzene M., Andrzejewska M., Kazimierczuk Z., Pinna L.A. 2004. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem. Biophys. Res. Commun. 321:1040–1044 10.1016/j.bbrc.2004.07.067 [PubMed] [Cross Ref]
  • Pagano M.A., Poletto G., Di Maira G., Cozza G., Ruzzene M., Sarno S., Bain J., Elliott M., Moro S., Zagotto G., et al. 2007. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. ChemBioChem. 8:129–139 10.1002/cbic.200600293 [PubMed] [Cross Ref]
  • Piehl C., Piontek J., Cording J., Wolburg H., Blasig I.E. 2010. Participation of the second extracellular loop of claudin-5 in paracellular tightening against ions, small and large molecules. Cell. Mol. Life Sci. 67:2131–2140 10.1007/s00018-010-0332-8 [PubMed] [Cross Ref]
  • Piontek J., Winkler L., Wolburg H., Müller S.L., Zuleger N., Piehl C., Wiesner B., Krause G., Blasig I.E. 2008. Formation of tight junction: determinants of homophilic interaction between classic claudins. FASEB J. 22:146–158 10.1096/fj.07-8319com [PubMed] [Cross Ref]
  • Prasad S., Mingrino R., Kaukinen K., Hayes K.L., Powell R.M., MacDonald T.T., Collins J.E. 2005. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab. Invest. 85:1139–1162 10.1038/labinvest.3700316 [PubMed] [Cross Ref]
  • Raleigh D.R., Marchiando A.M., Zhang Y., Shen L., Sasaki H., Wang Y., Long M., Turner J.R. 2010. Tight junction-associated MARVEL proteins marveld3, tricellulin, and occludin have distinct but overlapping functions. Mol. Biol. Cell. 21:1200–1213 10.1091/mbc.E09-08-0734 [PMC free article] [PubMed] [Cross Ref]
  • Rosenthal R., Milatz S., Krug S.M., Oelrich B., Schulzke J.D., Amasheh S., Günzel D., Fromm M. 2010. Claudin-2, a component of the tight junction, forms a paracellular water channel. J. Cell Sci. 123:1913–1921 10.1242/jcs.060665 [PubMed] [Cross Ref]
  • Ruzzene M., Di Maira G., Tosoni K., Pinna L.A. 2010. Assessment of CK2 constitutive activity in cancer cells. Methods Enzymol. 484:495–514 10.1016/B978-0-12-381298-8.00024-1 [PubMed] [Cross Ref]
  • Saitou M., Furuse M., Sasaki H., Schulzke J.D., Fromm M., Takano H., Noda T., Tsukita S. 2000. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol. Biol. Cell. 11:4131–4142 [PMC free article] [PubMed]
  • Sakakibara A., Furuse M., Saitou M., Ando-Akatsuka Y., Tsukita S. 1997. Possible involvement of phosphorylation of occludin in tight junction formation. J. Cell Biol. 137:1393–1401 10.1083/jcb.137.6.1393 [PMC free article] [PubMed] [Cross Ref]
  • Sarker R., Grønborg M., Cha B., Mohan S., Chen Y., Pandey A., Litchfield D., Donowitz M., Li X. 2008. Casein kinase 2 binds to the C terminus of Na+/H+ exchanger 3 (NHE3) and stimulates NHE3 basal activity by phosphorylating a separate site in NHE3. Mol. Biol. Cell. 19:3859–3870 10.1091/mbc.E08-01-0019 [PMC free article] [PubMed] [Cross Ref]
  • Sarno S., Reddy H., Meggio F., Ruzzene M., Davies S.P., Donella-Deana A., Shugar D., Pinna L.A. 2001. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 (‘casein kinase-2’). FEBS Lett. 496:44–48 10.1016/S0014-5793(01)02404-8 [PubMed] [Cross Ref]
  • Schmidt A., Utepbergenov D.I., Krause G., Blasig I.E. 2001. Use of surface plasmon resonance for real-time analysis of the interaction of ZO-1 and occludin. Biochem. Biophys. Res. Commun. 288:1194–1199 10.1006/bbrc.2001.5914 [PubMed] [Cross Ref]
  • Schmidt A., Utepbergenov D.I., Mueller S.L., Beyermann M., Schneider-Mergener J., Krause G., Blasig I.E. 2004. Occludin binds to the SH3-hinge-GuK unit of zonula occludens protein 1: potential mechanism of tight junction regulation. Cell. Mol. Life Sci. 61:1354–1365 10.1007/s00018-004-4010-6 [PubMed] [Cross Ref]
  • Schulzke J.D., Gitter A.H., Mankertz J., Spiegel S., Seidler U., Amasheh S., Saitou M., Tsukita S., Fromm M. 2005. Epithelial transport and barrier function in occludin-deficient mice. Biochim. Biophys. Acta. 1669:34–42 10.1016/j.bbamem.2005.01.008 [PubMed] [Cross Ref]
  • Schwark J.R., Jansen H.W., Lang H.J., Krick W., Burckhardt G., Hropot M. 1998. S3226, a novel inhibitor of Na+/H+ exchanger subtype 3 in various cell types. Pflugers Arch. 436:797–800 10.1007/s004240050704 [PubMed] [Cross Ref]
  • Seth A., Sheth P., Elias B.C., Rao R. 2007. Protein phosphatases 2A and 1 interact with occludin and negatively regulate the assembly of tight junctions in the CACO-2 cell monolayer. J. Biol. Chem. 282:11487–11498 10.1074/jbc.M610597200 [PubMed] [Cross Ref]
  • Shen L., Turner J.R. 2005. Actin depolymerization disrupts tight junctions via caveolae-mediated endocytosis. Mol. Biol. Cell. 16:3919–3936 10.1091/mbc.E04-12-1089 [PMC free article] [PubMed] [Cross Ref]
  • Shen L., Weber C.R., Turner J.R. 2008. The tight junction protein complex undergoes rapid and continuous molecular remodeling at steady state. J. Cell Biol. 181:683–695 10.1083/jcb.200711165 [PMC free article] [PubMed] [Cross Ref]
  • Shen L., Weber C.R., Raleigh D.R., Yu D., Turner J.R. 2011. Tight junction pore and leak pathways: a dynamic duo. Annu. Rev. Physiol. 73:283–309 10.1146/annurev-physiol-012110-142150 [PubMed] [Cross Ref]
  • Shin K., Margolis B. 2006. ZOning out tight junctions. Cell. 126:647–649 10.1016/j.cell.2006.08.005 [PubMed] [Cross Ref]
  • Siddiqui-Jain A., Drygin D., Streiner N., Chua P., Pierre F., O’Brien S.E., Bliesath J., Omori M., Huser N., Ho C., et al. 2010. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 70:10288–10298 10.1158/0008-5472.CAN-10-1893 [PubMed] [Cross Ref]
  • Simon D.B., Lu Y., Choate K.A., Velazquez H., Al-Sabban E., Praga M., Casari G., Bettinelli A., Colussi G., Rodriguez-Soriano J., et al. 1999. Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science. 285:103–106 10.1126/science.285.5424.103 [PubMed] [Cross Ref]
  • Smales C., Ellis M., Baumber R., Hussain N., Desmond H., Staddon J.M. 2003. Occludin phosphorylation: identification of an occludin kinase in brain and cell extracts as CK2. FEBS Lett. 545:161–166 10.1016/S0014-5793(03)00525-8 [PubMed] [Cross Ref]
  • Sundstrom J.M., Tash B.R., Murakami T., Flanagan J.M., Bewley M.C., Stanley B.A., Gonsar K.B., Antonetti D.A. 2009. Identification and analysis of occludin phosphosites: a combined mass spectrometry and bioinformatics approach. J. Proteome Res. 8:808–817 10.1021/pr7007913 [PubMed] [Cross Ref]
  • Suzuki T., Elias B.C., Seth A., Shen L., Turner J.R., Giorgianni F., Desiderio D., Guntaka R., Rao R. 2009. PKC eta regulates occludin phosphorylation and epithelial tight junction integrity. Proc. Natl. Acad. Sci. USA. 106:61–66 10.1073/pnas.0802741106 [PubMed] [Cross Ref]
  • Tamura A., Hayashi H., Imasato M., Yamazaki Y., Hagiwara A., Wada M., Noda T., Watanabe M., Suzuki Y., Tsukita S. 2011. Loss of claudin-15, but not claudin-2, causes Na(+) deficiency and glucose malabsorption in mouse small intestine. Gastroenterology. 140:913–923 10.1053/j.gastro.2010.08.006 [PubMed] [Cross Ref]
  • Tanaka M., Kamata R., Sakai R. 2005. EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates paracellular permeability. J. Biol. Chem. 280:42375–42382 10.1074/jbc.M503786200 [PubMed] [Cross Ref]
  • Tsukita S., Furuse M. 2000. Pores in the wall: claudins constitute tight junction strands containing aqueous pores. J. Cell Biol. 149:13–16 10.1083/jcb.149.1.13 [PMC free article] [PubMed] [Cross Ref]
  • Tsukita S., Furuse M. 2002. Claudin-based barrier in simple and stratified cellular sheets. Curr. Opin. Cell Biol. 14:531–536 10.1016/S0955-0674(02)00362-9 [PubMed] [Cross Ref]
  • Turner J.R. 2009. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 9:799–809 10.1038/nri2653 [PubMed] [Cross Ref]
  • Turner J.R., Rill B.K., Carlson S.L., Carnes D., Kerner R., Mrsny R.J., Madara J.L. 1997. Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am. J. Physiol. 273:C1378–C1385 [PubMed]
  • Turner J.R., Black E.D., Ward J., Tse C.M., Uchwat F.A., Alli H.A., Donowitz M., Madara J.L., Angle J.M. 2000. Transepithelial resistance can be regulated by the intestinal brush-border Na(+)/H(+) exchanger NHE3. Am. J. Physiol. Cell Physiol. 279:C1918–C1924 [PubMed]
  • Umeda K., Ikenouchi J., Katahira-Tayama S., Furuse K., Sasaki H., Nakayama M., Matsui T., Tsukita S., Furuse M., Tsukita S. 2006. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell. 126:741–754 10.1016/j.cell.2006.06.043 [PubMed] [Cross Ref]
  • Van Itallie C., Rahner C., Anderson J.M. 2001. Regulated expression of claudin-4 decreases paracellular conductance through a selective decrease in sodium permeability. J. Clin. Invest. 107:1319–1327 10.1172/JCI12464 [PMC free article] [PubMed] [Cross Ref]
  • Van Itallie C.M., Fanning A.S., Anderson J.M. 2003. Reversal of charge selectivity in cation or anion-selective epithelial lines by expression of different claudins. Am. J. Physiol. Renal Physiol. 285:F1078–F1084 [PubMed]
  • Van Itallie C.M., Colegio O.R., Anderson J.M. 2004. The cytoplasmic tails of claudins can influence tight junction barrier properties through effects on protein stability. J. Membr. Biol. 199:29–38 10.1007/s00232-004-0673-z [PubMed] [Cross Ref]
  • Van Itallie C.M., Gambling T.M., Carson J.L., Anderson J.M. 2005. Palmitoylation of claudins is required for efficient tight-junction localization. J. Cell Sci. 118:1427–1436 10.1242/jcs.01735 [PubMed] [Cross Ref]
  • Van Itallie C.M., Betts L., Smedley J.G., III, McClane B.A., Anderson J.M. 2008a. Structure of the claudin-binding domain of Clostridium perfringens enterotoxin. J. Biol. Chem. 283:268–274 10.1074/jbc.M708066200 [PubMed] [Cross Ref]
  • Van Itallie C.M., Holmes J., Bridges A., Gookin J.L., Coccaro M.R., Proctor W., Colegio O.R., Anderson J.M. 2008b. The density of small tight junction pores varies among cell types and is increased by expression of claudin-2. J. Cell Sci. 121:298–305 10.1242/jcs.021485 [PubMed] [Cross Ref]
  • Van Itallie C.M., Fanning A.S., Bridges A., Anderson J.M. 2009a. ZO-1 stabilizes the tight junction solute barrier through coupling to the perijunctional cytoskeleton. Mol. Biol. Cell. 20:3930–3940 10.1091/mbc.E09-04-0320 [PMC free article] [PubMed] [Cross Ref]
  • Van Itallie C.M., Holmes J., Bridges A., Anderson J.M. 2009b. Claudin-2-dependent changes in noncharged solute flux are mediated by the extracellular domains and require attachment to the PDZ-scaffold. Ann. N. Y. Acad. Sci. 1165:82–87 10.1111/j.1749-6632.2009.04052.x [PMC free article] [PubMed] [Cross Ref]
  • Van Itallie C.M., Fanning A.S., Holmes J., Anderson J.M. 2010. Occludin is required for cytokine-induced regulation of tight junction barriers. J. Cell Sci. 123:2844–2852 10.1242/jcs.065581 [PubMed] [Cross Ref]
  • Walter J.K., Castro V., Voss M., Gast K., Rueckert C., Piontek J., Blasig I.E. 2009. Redox-sensitivity of the dimerization of occludin. Cell. Mol. Life Sci. 66:3655–3662 10.1007/s00018-009-0150-z [PubMed] [Cross Ref]
  • Wang F., Graham W.V., Wang Y., Witkowski E.D., Schwarz B.T., Turner J.R. 2005. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am. J. Pathol. 166:409–419 10.1016/S0002-9440(10)62264-X [PubMed] [Cross Ref]
  • Weber C.R., Nalle S.C., Tretiakova M., Rubin D.T., Turner J.R. 2008. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab. Invest. 88:1110–1120 10.1038/labinvest.2008.78 [PMC free article] [PubMed] [Cross Ref]
  • Weber C.R., Raleigh D.R., Su L., Shen L., Sullivan E.A., Wang Y., Turner J.R. 2010. Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J. Biol. Chem. 285:12037–12046 10.1074/jbc.M109.064808 [PMC free article] [PubMed] [Cross Ref]
  • Wittchen E.S., Haskins J., Stevenson B.R. 1999. Protein interactions at the tight junction. Actin has multiple binding partners, and ZO-1 forms independent complexes with ZO-2 and ZO-3. J. Biol. Chem. 274:35179–35185 10.1074/jbc.274.49.35179 [PubMed] [Cross Ref]
  • Wong V. 1997. Phosphorylation of occludin correlates with occludin localization and function at the tight junction. Am. J. Physiol. 273:C1859–C1867 [PubMed]
  • Yu A.S., McCarthy K.M., Francis S.A., McCormack J.M., Lai J., Rogers R.A., Lynch R.D., Schneeberger E.E. 2005. Knockdown of occludin expression leads to diverse phenotypic alterations in epithelial cells. Am. J. Physiol. Cell Physiol. 288:C1231–C1241 10.1152/ajpcell.00581.2004 [PubMed] [Cross Ref]
  • Yu A.S., Cheng M.H., Angelow S., Günzel D., Kanzawa S.A., Schneeberger E.E., Fromm M., Coalson R.D. 2009. Molecular basis for cation selectivity in claudin-2-based paracellular pores: identification of an electrostatic interaction site. J. Gen. Physiol. 133:111–127 10.1085/jgp.200810154 [PMC free article] [PubMed] [Cross Ref]
  • Yu D., Marchiando A.M., Weber C.R., Raleigh D.R., Wang Y., Shen L., Turner J.R. 2010. MLCK-dependent exchange and actin binding region-dependent anchoring of ZO-1 regulate tight junction barrier function. Proc. Natl. Acad. Sci. USA. 107:8237–8241 10.1073/pnas.0908869107 [PubMed] [Cross Ref]
  • Zeissig S., Bürgel N., Günzel D., Richter J., Mankertz J., Wahnschaffe U., Kroesen A.J., Zeitz M., Fromm M., Schulzke J.D. 2007. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut. 56:61–72 10.1136/gut.2006.094375 [PMC free article] [PubMed] [Cross Ref]
  • Zolotarevsky Y., Hecht G., Koutsouris A., Gonzalez D.E., Quan C., Tom J., Mrsny R.J., Turner J.R. 2002. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology. 123:163–172 10.1053/gast.2002.34235 [PubMed] [Cross Ref]

Articles from The Journal of Cell Biology are provided here courtesy of The Rockefeller University Press